CONT SUB-SCHEDULE II-90-DAY

104th Regular Session Introduced by Mike Simmons-Gessesse

Illinois SB 3764 aims to modify Schedule II drug regulations under a 90-day framework, affecting prescribing, dispensing, and oversight for controlled substances.

Rule 3-9(a) / Re-referred to Assignments

Summary of SB 3764 (104th Illinois General Assembly)

Purpose and intent

The bill is titled CONT SUB-SCHEDULE II-90-DAY, suggesting a focus on controlled substances regulation, specifically an expansion or modification related to Schedule II medications under a 90-day framework. The exact policy goals are not stated in the provided action history, but the title and related committee references imply adjustments to controlled substance scheduling, dispensing, or oversight within Illinois.

Key provisions and changes (provisional, based on title and typical scope)

Likely adjustments to the Illinois Controlled Substances Act or related regulations governing Schedule II drugs (e.g., morphine, oxycodone, stimulants) and the handling of substances listed on Schedule II.

Potential changes may include:

Modifications to prescribing requirements, dispensing limits, or recordkeeping for Schedule II medications.
Introduction or clarification of a 90-day regulatory framework or supply cycle for certain Schedule II substances.
Rules governing scheduling, transfer, or renewal processes for licenses or registrations related to controlled substances.

Because the bill’s text is not provided, these points are inferred from the title and common legislative patterns.

Who or what would be affected

Health care professionals and facilities that prescribe, dispense, or administer Schedule II controlled substances (e.g., physicians, pharmacists, clinics, hospitals).

Entities holding licenses or registrations under Illinois controlled substances laws (e.g., pharmacies, prescribers, wholesalers).

Patients and consumers who rely on Schedule II medications, particularly those affected by changes to prescribing/dispensing workflows or supply cycles.

Procedural and timeline aspects

Filing and sponsorship:

Filed with the Secretary and introduced by Sen. Mike Simmons.
Co-sponsored by Mike Simmons and Gessesse.

Referral history:

Initially referred to the Assigned committee (Feb 5, 2026).
Moved to Licensed Activities (Feb 24, 2026).
Re-referred to Assignments (Mar 27, 2026) after progressing through committee steps.

Committee deadlines:

Rule 2-10 establishes a committee deadline for the bill as March 27, 2026.
Rule 3-9(a) indicates a re-referral to Assignments on March 27, 2026, signaling continued consideration or disposition adjustments.

Status implication:

The bill is in the early-to-mid stages of legislative consideration, with committee routing and potential amendments possible before floor action.

Notable considerations for readers

The exact statutory language is not provided here; for precise requirements, one would need to review the bill’s text, fiscal impact statement, and any amendments adopted during committee or floor debate.

If you are a regulated entity (e.g., pharmacist, prescriber, pharmacy administrator), monitor for changes to licensing, dispensing, recordkeeping, or renewal procedures that could affect compliance timelines.

For public health stakeholders, changes to Schedule II controls can influence pain management practices, substance use treatment coordination, and regulatory oversight.

If you’d like, I can locate the full bill text and provide a more detailed, section-by-section breakdown of provisions and potential impacts.